Skip to main content
Erschienen in: AIDS and Behavior 7/2012

01.10.2012 | Original Paper

“Tell Juliana”: Acceptability of the Candidate Microbicide VivaGel® and Two Placebo Gels Among Ethnically Diverse, Sexually Active Young Women Participating in a Phase 1 Microbicide Study

verfasst von: Alex Carballo-Diéguez, Rebecca Giguere, Curtis Dolezal, Beatrice A. Chen, Jessica Kahn, Greg Zimet, Marina Mabragaña, Cheng-Shiun Leu, Ian McGowan

Erschienen in: AIDS and Behavior | Ausgabe 7/2012

Einloggen, um Zugang zu erhalten

Abstract

This study assessed acceptability of the candidate microbicide VivaGel® and two placebo gels among 61 sexually active young US and Puerto Rican women at three sites. Participants were randomly assigned to use one of the gels twice per day for 14 days. At trial completion, 59% of the women in the VivaGel® group reported being likely to use the gel in the future, whereas 23% were unlikely to use it and 18% were undecided. Participants reported problems with all three gels, including the “universal” placebo containing hydroxyethyl cellulose (HEC). The most frequent complaints were leakage, interference with sexual behavior, and decreased sexual satisfaction. Some of the complaints are not new but remain unresolved. Women’s perceived risk of HIV infection may determine whether the gels are used. Users also may want a choice of viscosity. Poor acceptability of vaginal microbicide formulations may result in poor adherence to gel use during efficacy trials and compromise validity of results.
Literatur
1.
Zurück zum Zitat Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168–74.PubMedCrossRef Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168–74.PubMedCrossRef
2.
Zurück zum Zitat Mantell JE, Myer L, Carballo-Diéguez A, et al. Microbicide acceptability research: current approaches and future directions. Soc Sci Med. 2005;60(2):319–30.PubMedCrossRef Mantell JE, Myer L, Carballo-Diéguez A, et al. Microbicide acceptability research: current approaches and future directions. Soc Sci Med. 2005;60(2):319–30.PubMedCrossRef
3.
Zurück zum Zitat Coly A, Gorbach PM. Microbicide acceptability research: recent findings and evolution across phases of product development. Curr Opin HIV AIDS. 2008;3(5):581–6.PubMedCrossRef Coly A, Gorbach PM. Microbicide acceptability research: recent findings and evolution across phases of product development. Curr Opin HIV AIDS. 2008;3(5):581–6.PubMedCrossRef
4.
Zurück zum Zitat Severy LJ, Tolley E, Woodsong C, Guest G. A framework for examining the sustained acceptability of microbicides. AIDS Behav. 2005;9(1):121–31.PubMedCrossRef Severy LJ, Tolley E, Woodsong C, Guest G. A framework for examining the sustained acceptability of microbicides. AIDS Behav. 2005;9(1):121–31.PubMedCrossRef
5.
Zurück zum Zitat Morrow KM, Ruiz MS. Assessing microbicide acceptability: a comprehensive and integrated approach. AIDS Behav. 2008;12(2):272–83.PubMedCrossRef Morrow KM, Ruiz MS. Assessing microbicide acceptability: a comprehensive and integrated approach. AIDS Behav. 2008;12(2):272–83.PubMedCrossRef
6.
Zurück zum Zitat Bentley ME, Morrow KM, Fullem A, et al. Acceptability of a novel vaginal microbicide during a safety trial among low-risk women. Fam Plan Perspect. 2000;32(4):184–8.CrossRef Bentley ME, Morrow KM, Fullem A, et al. Acceptability of a novel vaginal microbicide during a safety trial among low-risk women. Fam Plan Perspect. 2000;32(4):184–8.CrossRef
7.
Zurück zum Zitat Rosen RK, Morrow KM, Carballo-Diéguez A, et al. Acceptability of tenofovir gel as a vaginal microbicide among women in a phase I trial: a mixed-methods study. J Womens Health. 2008;17(3):383–92.CrossRef Rosen RK, Morrow KM, Carballo-Diéguez A, et al. Acceptability of tenofovir gel as a vaginal microbicide among women in a phase I trial: a mixed-methods study. J Womens Health. 2008;17(3):383–92.CrossRef
8.
Zurück zum Zitat Whitehead SJ, Kilmarx PH, Blanchard K, et al. Acceptability of Carraguard vaginal gel use among Thai couples. AIDS. 2006;20(17):2141–8.PubMedCrossRef Whitehead SJ, Kilmarx PH, Blanchard K, et al. Acceptability of Carraguard vaginal gel use among Thai couples. AIDS. 2006;20(17):2141–8.PubMedCrossRef
9.
Zurück zum Zitat Joglekar N, Joshi S, Kakde M, et al. Acceptability of PRO2000 vaginal gel among HIV un-infected women in Pune, India. AIDS Care. 2007;19(6):817–21.PubMedCrossRef Joglekar N, Joshi S, Kakde M, et al. Acceptability of PRO2000 vaginal gel among HIV un-infected women in Pune, India. AIDS Care. 2007;19(6):817–21.PubMedCrossRef
10.
Zurück zum Zitat Morrow K, Rosen R, Richter L, et al. The acceptability of an investigational vaginal microbicide, PRO 2000 Gel, among women in a phase I clinical trial. J Womens Health. 2003;12(7):655–66.CrossRef Morrow K, Rosen R, Richter L, et al. The acceptability of an investigational vaginal microbicide, PRO 2000 Gel, among women in a phase I clinical trial. J Womens Health. 2003;12(7):655–66.CrossRef
11.
Zurück zum Zitat Mason TH, Foster SE, Finlinson HA, et al. Perspectives related to the potential use of vaginal microbicides among drug-involved women: focus groups in three cities in the United States and Puerto Rico. AIDS Behav. 2003;7(4):339–51.PubMedCrossRef Mason TH, Foster SE, Finlinson HA, et al. Perspectives related to the potential use of vaginal microbicides among drug-involved women: focus groups in three cities in the United States and Puerto Rico. AIDS Behav. 2003;7(4):339–51.PubMedCrossRef
12.
Zurück zum Zitat Bentley ME, Fullem AM, Tolley EE, et al. Acceptability of a microbicide among women and their partners in a 4-country phase I trial. Am J Public Health. 2004;94(7):1159–64.PubMedCrossRef Bentley ME, Fullem AM, Tolley EE, et al. Acceptability of a microbicide among women and their partners in a 4-country phase I trial. Am J Public Health. 2004;94(7):1159–64.PubMedCrossRef
13.
Zurück zum Zitat McGowan I, Gomez K, Bruder K, et al. Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel®) in sexually active young women (MTN-004). AIDS. 2011;25(8):1057–64.PubMedCrossRef McGowan I, Gomez K, Bruder K, et al. Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel®) in sexually active young women (MTN-004). AIDS. 2011;25(8):1057–64.PubMedCrossRef
14.
Zurück zum Zitat SPSS Inc. SPSS for Windows, Rel. 17.0.0.2008. Chicago, IL. SPSS Inc. SPSS for Windows, Rel. 17.0.0.2008. Chicago, IL.
15.
Zurück zum Zitat Mâsse BR, Boily MC, Dimitrov D, Desai K. Efficacy dilution in randomized placebo-controlled vaginal microbicide trials. Emerg Themes Epidemiol. 2009;6:5.PubMedCrossRef Mâsse BR, Boily MC, Dimitrov D, Desai K. Efficacy dilution in randomized placebo-controlled vaginal microbicide trials. Emerg Themes Epidemiol. 2009;6:5.PubMedCrossRef
16.
Zurück zum Zitat Jenness SM, Begier EM, Neaigus A, Murrill CS, Wendel T, Hagan H. Unprotected anal intercourse and sexually transmitted diseases in high-risk heterosexual women. Am J Public Health. 2011;101(4):745–50.PubMedCrossRef Jenness SM, Begier EM, Neaigus A, Murrill CS, Wendel T, Hagan H. Unprotected anal intercourse and sexually transmitted diseases in high-risk heterosexual women. Am J Public Health. 2011;101(4):745–50.PubMedCrossRef
17.
Zurück zum Zitat Maynard E, Carballo-Diéguez A, Ventuneac A, Exner T, Mayer K. Women’s experiences with anal sex: motivations and implications for STD prevention. Perspect Sex Reprod Health. 2009;41(3):142–9.PubMedCrossRef Maynard E, Carballo-Diéguez A, Ventuneac A, Exner T, Mayer K. Women’s experiences with anal sex: motivations and implications for STD prevention. Perspect Sex Reprod Health. 2009;41(3):142–9.PubMedCrossRef
18.
Zurück zum Zitat Leynaert B, Downs AM, de Vincenzi I. Heterosexual transmission of human immunodeficiency virus: variability of infectivity throughout the course of infection. European Study Group on Heterosexual Transmission of HIV. Am J Epidemiol. 1998;148(1):88–96.PubMedCrossRef Leynaert B, Downs AM, de Vincenzi I. Heterosexual transmission of human immunodeficiency virus: variability of infectivity throughout the course of infection. European Study Group on Heterosexual Transmission of HIV. Am J Epidemiol. 1998;148(1):88–96.PubMedCrossRef
19.
Zurück zum Zitat Vernazza PL, Eron JJ, Fiscus SA, Cohen MS. Sexual transmission of HIV: infectiousness and prevention. AIDS. 1999;13(2):155–66.PubMedCrossRef Vernazza PL, Eron JJ, Fiscus SA, Cohen MS. Sexual transmission of HIV: infectiousness and prevention. AIDS. 1999;13(2):155–66.PubMedCrossRef
20.
Zurück zum Zitat Mastro TD, de Vincenzi I. Probabilities of sexual HIV-1 transmission. AIDS. 1996;10(Suppl A):S75–82.PubMedCrossRef Mastro TD, de Vincenzi I. Probabilities of sexual HIV-1 transmission. AIDS. 1996;10(Suppl A):S75–82.PubMedCrossRef
Metadaten
Titel
“Tell Juliana”: Acceptability of the Candidate Microbicide VivaGel® and Two Placebo Gels Among Ethnically Diverse, Sexually Active Young Women Participating in a Phase 1 Microbicide Study
verfasst von
Alex Carballo-Diéguez
Rebecca Giguere
Curtis Dolezal
Beatrice A. Chen
Jessica Kahn
Greg Zimet
Marina Mabragaña
Cheng-Shiun Leu
Ian McGowan
Publikationsdatum
01.10.2012
Verlag
Springer US
Erschienen in
AIDS and Behavior / Ausgabe 7/2012
Print ISSN: 1090-7165
Elektronische ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-011-0028-6

Weitere Artikel der Ausgabe 7/2012

AIDS and Behavior 7/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Ist Fasten vor Koronarinterventionen wirklich nötig?

Wenn Eingriffe wie eine Koronarangiografie oder eine Koronarangioplastie anstehen, wird häufig empfohlen, in den Stunden zuvor nüchtern zu bleiben. Ein französisches Forscherteam hat diese Maßnahme hinterfragt.

Typ-2-Diabetes: Ernährungsunsicherheit vervierfacht Risiko für schwere Hypoglykämien

04.06.2024 Typ-2-Diabetes Nachrichten

Wenn ältere Menschen mit Typ-2-Diabetes Schwierigkeiten beim Beschaffen und Zubereiten von Mahlzeiten haben, geht dies mit einem deutlich gesteigerten Risiko für schwere Hypoglykämien einher.

Mehr Brustkrebs, aber weniger andere gynäkologische Tumoren mit Levonorgestrel-IUS

04.06.2024 Levonorgestrel Nachrichten

Unter Frauen, die ein Levonorgestrel-freisetzendes intrauterines System (IUS) verwenden, ist die Brustkrebsrate um 13% erhöht. Dafür kommt es deutlich seltener zu Endometrium-, Zervix- und Ovarialkarzinomen.

GLP-1-Agonist Semaglutid wirkt kardio- und nephroprotektiv

03.06.2024 Semaglutid Nachrichten

Der GLP-1-Agonist Semaglutid hat in der FLOW-Studie bewiesen, dass sich damit die Progression chronischer Nierenerkrankungen bei Patienten mit Typ-2-Diabetes bremsen lässt. Auch in kardiovaskulärer Hinsicht war die Therapie erfolgreich.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.